Status:

COMPLETED

Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages

Lead Sponsor:

Profil Institut für Stoffwechselforschung GmbH

Collaborating Sponsors:

European Union

Conditions:

Diabetes Mellitus Type 1

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

The ultimate goal of the PCDIAB project is to develop a bi-hormonal pump (insulin and glucagon) substituting for the pancreas and facilitating tight euglycemic control in patients with T1DM.

Detailed Description

The study is planned as open, randomised 3-period cross-over in patients with T1DM. The study will include a total of 6 completing patients. The study is not blinded due to the exploratory nature. At...

Eligibility Criteria

Inclusion

  • Male or female subjects with diabetes mellitus type 1 , as defined by the American Diabetes Association1.
  • Age ≥ 18 and ≤ 65 years.

Exclusion

  • Known or suspected hypersensitivity to trial product(s) or related products.
  • Receipt of any investigational medicinal product within 3 months or 5 half-lives of that IMP before randomisation in this trial.

Key Trial Info

Start Date :

August 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2013

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT01916265

Start Date

August 1 2013

End Date

November 1 2013

Last Update

February 5 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Profil Institut für Stoffwechselforschung GmbH

Neuss, North Rhine-Westphalia, Germany, 41460

Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages | DecenTrialz